Heart rhythm
Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib.
Emily Tomasulo, Andy Itsara, Mark Haigney, Douglas R Rosing, Inhye E Ahn, Cody Peer, Beth A Kozel, Teresa Luperchio, Grace Ge, William D Figg, Adrian Wiestner, Clare Sun
Published: 202510.1016/j.hrthm.2025.10.014
Abstract
BACKGROUND: Ibrutinib (IBR) is a first-in-class Bruton's tyrosine kinase inhibitor (BTKi) approved in multiple hematologic conditions for indefinite use until disease progression or toxicity. Hypertension and atrial fibrillation are well-recognized c…
Preview only. Read the full abstract at the source